Multiple myeloma (MM) is a clonal plasma cell tumour that requires systemic treatment once disease-related symptoms arise. Symptomatic MM is defined by at least one of the following: hypercalcaemia, renal failure, anaemia and/or bone lesions. Several therapeutic milestones have been achieved during the last few decades, resulting in improved prognosis for affected subjects. The alkylator melphalan has been a backbone of MM treatment since its introduction in the 1960s. The compound is currently used at high doses followed by autologous stem cell transplantation (ASCT) in patients ≤65-70 years of age in conventional doses in conjunction with prednisone and either thalidomide (MPT) or the proteasome inhibitor bortezomib (VMP). Both regimens have proved superior to MP alone in randomised clinical trials. In patients eligible for ASCT, initial cytoreduction should be performed using one of the 'novel' compounds (thalidomide, bortezomib, lenalidomide) in combination with dexamethasone because of enhanced response both before and after ASCT compared with standard anthracycline/dexamethasone. However, it has not yet been determined which combination should best be used in a given patient.
anaemia and bone disease [CRAB] ) is considered to be symptomatic myeloma and thus requires treatment. 2 The initial attempts to bring cytotoxic chemotherapy to myeloma patients in the late 1960s consisted of drug combinations utilising the alkylator melphalan and corticosteroids. 3, 4 Melphalan and prednisone (MP) was considered the standard of care for patients with MM in the following years. Attempts to achieve disease control and survival rates beyond those seen with the use of MP by intensive chemotherapy combinations were not successful: an analysis of individual patient data combined with a meta-analysis of 27 trials revealed no difference in mortality rate for patients treated with MP compared with those receiving combination chemotherapy. 
High-dose Chemotherapy with Autologous Stem Cell Transplantation
Substantially increasing the dose of melphalan provided the basis for the first major breakthrough in myeloma treatment: the introduction of high-dose chemotherapy with subsequent retransfusion of autologous peripheral blood progenitor cells (APBPCs). Initial reports of doseintensified melphalan (still without APBPC transplant) appeared in the early 1980s. Response to therapy in the first small series on nine subjects was remarkable, especially in those few who had received no prior treatment. 6 However, a major obstacle was the high rate of infectious complications associated with a number of treatment-related deaths due to profound and long-lasting neutropenia. The administration of granulocyte-macrophage colony-stimulating factor easily accessible. [8] [9] [10] The first randomised trial documented high-dose therapy with autologous stem cell transplantation to be superior to conventional treatment in terms of response, progression-free survival (PFS) and overall survival (OS) in 1996. 11 Since then, this modality has been widely adopted as a standard of care in up-front management for subjects with newly diagnosed disease up to 65 years of age. Those results should be interpreted with caution as they are based on retrospective analyses.
Autologous Transplantation in Elderly Subjects
Whether high-dose chemotherapy and APBPC transplantation also improves treatment outcomes in subjects >60 years of age has been a matter of debate. In an Italian protocol, previously untreated patients between 55 and 75 years of age (median 64 years) were to receive three cycles of melphalan 100mg/m 2 each followed by transplantation of APBPCs. Their outcomes were compared with pair mates having received standard MP: the dose-reduced 'high-dose' protocol was feasible and no toxic deaths occurred. Significantly, more complete responses were seen following autologous transplant, event-free survival (EFS) was doubled and even OS was significantly increased compared with standard treatment. 17 However, advances in myeloma treatment may challenge standards of care in relatively short intervals of time; this was true for a three-arm randomised trial by the French IFM group in subjects between 65 and 75 years of age.
Patients were to receive -apart from standard MP and one cycle of high-dose melphalan 100mg/m 2 -MP plus thalidomide. 18 Thalidomide, a compound with anti-angiogenic and anti-inflammatory properties, is known to be effective in MM and has been extensively studied in both newly diagnosed and relapsed disease. [19] [20] [21] In this three-arm trial, MP plus thalidomide (MPT regimen) yielded the best results in terms of response rate, PFS and OS. Therefore, the authors concluded that MPT should be the new standard of care in elderly myeloma patients.
A slightly longer time to event (EFS) was observed in a German months with MP in a randomised trial. Despite high-quality response being in favour of TD, OS for this arm was significantly shorter compared with MP. 28 One explanation for these results was the higher toxicity seen with TD in frail elderly subjects; however, one might speculate on the impact of an alkylator (melphalan) for longevity of remission achieved. Based on the results of a phase I/II trial, the combination of the first-in-class proteasome inhibitor bortezomib
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with MP (VMP) versus MP alone was subsequently tested in a randomised phase III study: patients allocated to VMP had better outcomes for response rate and all survival parameters and also achieved responses more rapidly. 30 A subgroup analysis suggested that VMP is also active in unfavourable months and a two-year OS of 91% 32 (see Table 1 ).
Novel Compounds in Patients Eligible for Transplantation
TD given to patients with newly diagnosed MM resulted in significantly more severe (grade >3) toxicity compared with high-dose dexamethasone alone: 45% for TD versus 21% for dexamethasone.
However, the response rate was significantly higher in the combination arm (63 versus 41%). 33 The difference in response favouring TD over dexamethasone was retained in a larger phase III trial, while the difference in grade 4 toxicity was less pronounced (30% TD versus 23% dexamethasone). 34 Since it is currently not known Bortezomib/dexamethasone (VelDex) given to patients <65 years of age with untreated myeloma resulted in significantly higher overall response rate (ORR) and higher VGPR when randomly compared with standard VAD in a French trial. 37 Those results were valid for assessment before and after high-dose chemotherapy. At a relatively short follow-up, two-year PFS was significantly extended following VelDex, but did not translate into superior OS at two years from randomisation. Recently, the German DSMM group reported an interim analysis on an ongoing up-front trial. Bortezomib, cyclophosphamide and dexamethasone (VelCD) was administered to patients with newly diagnosed disease before stem cell transplant. 38 The maximum tolerated dose of cyclophosphamide had previously been determined to be 900mg/m 2 on cycle day one. 39 The ORR to VelCD was 84%, and in the interim analysis no statistically significant differences of response in relation to presence of adverse cytogenetic factors including del(17p) were detected. The thalidomide analogue lenalidomide (Revlimid ® ) is known to be effective in relapsed MM. A study investigated this immunomodulatory drug with dexamethasone in treatment-naïve patients randomly comparing conventional-dose (RD) with dose-reduced dex (Rd). 40 Not only was toxicity significantly
Haematological Malignancies Lymphoproliferative Disorders higher in the RD group, but also the one-year OS favoured reduced- 
Stem Cell Mobilisation in Combinations of Novel Drugs
In contrast to the previous trial, significant impairment of stem cell mobilisation utilising R in conjunction with cyclophosphamide and dexamethasone was reported by a group from the Mayo Clinic. 42 A trend towards a lower yield of CD34 + APBPCs was also reported from the bortezomib/dexamethasone arm of the French IFM 2005/01 trial, 37 and two groups from the US observed difficulties in mobilisation after initial lenalidomide-based treatment. 42, 43 Recently, these unforeseen events prompted the International Myeloma Working Group to publish recommendations in terms of safe and adequate stem cell collection for subjects receiving at least one of the novel drugs for induction. 44 The group's summary was steady-state mobilisation using G-CSF alone to be adequate for thalidomide/dexamethasone and bortezomib/ dexamethasone, irrespective of further disease-and patient-related variables. For patients ≥65 years and/or receiving lenalidomide/ dexamethasone induction beyond four cycles, G-CSF alone is no longer recommended and should be replaced by cyclophosphamide + G-CSF. This approach should be used as first-line therapy in all cases when additional cytotoxic drugs were used in addition to lenalidomide/dexamethasone.
Allogeneic Stem Cell Transplantation as a First-line Approach
The efficacy of allo-SCT is mainly based on immune control of the malignant disease by donor-derived lymphocytes; however, direct cytotoxic effects from the conditioning regimen may add to response.
Results from early trials employing myeloablative conditioning such as busulphan/cyclophosphamide were discouraging as they showed high transplant-related mortality (TRM) rates. . In all, optimal timing, conditioning regimen and patient-and disease-specific characteristics need to be determined to render allo-SCT a suitable first-line regimen for larger patient cohorts.
Conclusion
During the past two decades, significant progress has been made in first-line therapy for MM by both transplantation-and pharmacotherapybased approaches. Currently, high-dose melphalan 200mg/m 2 with support of APBPCs following cytoreduction with novel agent + dexamethasone (it is unclear whether the additional cytostatic agent contributes to enhanced outcome) can be considered a standard of care
for patients up to 65-70 years of age. It is still a matter of debate whether immediate autotransplant needs to be performed in subjects with excellent remission following induction treatment. Deferred highdose therapy (i.e. at first disease progression) may be an option that does not worsen a given patient's prognosis. For transplant-eligible subjects, allogeneic-RIC transplant may offer extension of treatmentfree intervals and even cure; however, optimal timing and patient selection should be further elucidated. As relapse occurs late after allo-SCT, drugs preferably with immunomodulatory properties may add to more durable disease control. In elderly subjects, melphalan/prednisone plus a novel agent represents a breakthrough after decades of stagnation. Whether melphalan/prednisone given in conjunction with a novel drug may be substituted for dexamethasone seems unclear given that TD was not superior to MP in a randomised comparison. n
